GlassScriptPhysician profile
Edward A Laubach
NPI 1104853696
$10,880.28
in general payments reported to CMS, 2019-2025
24 companies · $1,978 in 2025
The $1,978 reported for 2025 was more than what 97% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $839 · 2021: $2,494 · 2022: $898 · 2023: $1,293 · 2024: $2,356 · 2025: $1,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,072 · Travel and Lodging: $313 · Entertainment: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,071.76 |
| Travel and Lodging | $313.42 |
| Entertainment | $241.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,722.72 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Coopervision INC. | $2,585.75 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Ortho-K Contact Lens |
| Bausch & Lomb Americas INC. | $775.27 | 2022-2025 | Miebo, Xiidra, Infuse Multifocal |
| Sun Pharmaceutical Industries INC. | $690.43 | 2020-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $634.80 | 2019-2021 | |
| Visioneering Technologies, INC. | $320.65 | 2019-2025 | |
| Oyster Point Pharma, INC. | $299.84 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $247.23 | 2022-2025 | |
| Optos, INC. | $241.58 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Heru, INC. | $165.36 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $164.75 | 2024-2025 | Xdemvy |
| Sight Sciences, INC. | $155.57 | 2019-2024 | Tearcare System |
| Dompe US, INC. | $145.53 | 2024-2025 | Oxervate |
| Johnson & Johnson Vision Care, INC. | $140.87 | 2023-2024 | Axert, Acuvue |
| Aerie Pharmaceuticals, INC. | $135.41 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $121.27 | 2021 | |
| Biotissue Holdings INC. | $80.00 | 2021-2022 | |
| Thea Pharma INC. | $63.92 | 2023-2025 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $41.19 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $39.60 | 2019-2020 | |
| Harrow Eye, LLC | $29.81 | 2024 | Vevye |
| Mallinckrodt Hospital Products INC. | $29.39 | 2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $27.43 | 2021 | |
| Mallinckrodt Enterprises LLC | $21.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Laubach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.